News

cormatrix, cardiovascular, cardiovascular repair

CorMatrix Cardiovascular announced that it has received U.S. Food and Drug Administration (FDA) clearance to market the CorMatrix ECM for Vascular Repair.

July 22, 2014 — AtriCure announced it has sold more than 34,000 AtriClip left atrial appendage (LAA) exclusion system devices worldwide.

Boston Scientific Louts Tavi System CE mark Heart Repair

Boston Scientific Corp. received CE mark and began the European commercial launch of its new 25 mm Lotus transcatheter aortic valve implantation (TAVI) System, complementing the...

The Children's Hospital of Philadelphia (CHOP) launched the Fetal Neuroprotection and Neuroplasticity Program. 

CorMatrix Cardiovascular ECM Enrollment RESTORE Study Poland

CorMatrix Cardiovascular and the Central Clinical Hospital of the Ministry of Interior in Warsaw (Centralny Szpital Kliniczny MSW) of Warsaw, Poland, announced the successful enrollment and...

DC Devices Inc. has closed a $34 million Series D financing round. Accelmed led the round with contributions from existing investors Third Rock Ventures, General Catalyst Partners and Lumira...

CardiAQ Valve Technologies (CardiAQ), a leader in the field of transcatheter mitral valve implantation (TMVI), announced that the European Patent Office Legal Division issued a temporary stay of...

Revivent Myocardial Anchoring System BioVentrix 50th Heart Failure Treatment

BioVentrix announced the successful completion of it 50th clinical case using the Revivent myocardial anchoring system in a 74-year-old male patient at the OLV Hospital in Aalst, Belgium....

Researchers have announced the results of a study that used speckle-tracking echocardiography (STE) to analyze early phase one results from the multi-center COMPASSION trial, which seeks to...

June 23, 2014 — Edwards Lifesciences Corp. announced that three-year clinical outcomes of its Edwards Intuity valve platform demonstrated improved cardiac and valvular performance, as well as...

Less aggressive anticoagulation therapy, combined with low-dose aspirin, can be used safely in conjunction with a newer generation mechanical heart valve. These findings from the first phase of a...

Sapien XT, FDA

The U.S. Food and Drug Administration (FDA) approval for its Edwards Sapien XT transcatheter aortic heart valve for the treatment of high-risk and inoperable patients suffering from severe...

Watchman, LAA occluder

Interventional thought leaders at the American College of Cardiology (ACC) 2014 meeting shared their predictions about the cutting-edge technologies emerging today that will become commonplace in...

June 16, 2014 — PolyNova, a startup company that has grown out of an inter-institutional collaboration between the University of Arizona (UA) and Stony Brook University, announced it is developing...

June 16, 2014 — Boston Scientific Corp. has initiated the RESPOND post-market registry to assess real-world performance of the Lotus valve system. The RESPOND registry will collect data on...

Medtronic announced it is purchasing Covidien in a cash-and-stock deal for $42.9 billion. Once the transaction is completed, Medtronic will have significantly advanced its position as a premier...

Capricor Therapeutics Inc. announced the execution of an Exclusive License Agreement with Cedars-Sinai Medical Center for intellectual property (IP) related to the development of exosomes. ...

Medtronic 3f Enable Aortic Bioprosthesis Valve Repair Cardiovascular Surgery

Medtronic Inc. announced five-year follow-up data demonstrating the safety and performance of the Medtronic 3f Enable Aortic Bioprosthesis — the world's first commercially available sutureless...

Researchers at the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting (SNMMI) revealed how a protein encourages the production of stem cells that regenerate damaged tissues of...

June 5, 2014 — Lumedx Corp. and Scientific Software Solutions Inc. (SSS), maker of PedCath congenital catheterization reporting software, announced they are partnering to create an innovative...